<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Progabide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00837</strong>&#160; (APRD00072)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the <span class="caps">GABAA</span> and <span class="caps">GABAB</span> receptors. Progabide has been investigated for many diseases besides epilepsy, including Parkinson&#8217;s disease, schizophrenia, clinical depression and anxiety disorder with varying success.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00837/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00837/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00837.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00837.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00837.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00837.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00837.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00837">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Halogabide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Progabida</td><td>Spanish</td><td>INN</td></tr><tr><td>Progabide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Progabidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Gabren</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gabrene</td><td>Sanofi S.A.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antiparkinson-agents">Antiparkinson Agents</a></li>
<li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li>
<li><a href="/mesh/gaba-agonists">GABA Agonists</a></li>
<li><a href="/mesh/antidyskinetics">Antidyskinetics</a></li></ul></td></tr><tr><th>CAS number</th><td>62666-20-0</td></tr><tr><th>Weight</th><td>Average: 334.773<br>Monoisotopic: 334.088433678</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>16</sub>ClFN<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>DWEQWXSKOHHBNT-SAPNQHFASA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,21H,1-2,9H2,(H2,20,23)/b17-14+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-{[(4-chlorophenyl)[(1E)-3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene]methyl]amino}butanamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(=O)CCCN\C(C1=CC=C(Cl)C=C1)=C1/C=C(F)C=CC1=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Gamma Amino Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>o-Quinomethanes; Chlorobenzenes; Aryl Chlorides; Primary Carboxylic Acid Amides; Enolates; Polyamines; Carboxylic Acids; Enamines; Organofluorides; Organochlorides</td></tr><tr><th>Substituents</th><td>o-quinomethane; quinomethane; chlorobenzene; aryl chloride; aryl halide; benzene; carboxamide group; primary carboxylic acid amide; ketone; carboxylic acid; enolate; enamine; polyamine; organofluoride; organochloride; organohalogen; carbonyl group; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated for the treatment of epilepsy.</td></tr><tr><th>Pharmacodynamics</th><td>Progabide, a fatty acid derivative, is a GABA receptor agonist used to treat the symptoms of epilepsy.</td></tr><tr><th>Mechanism of action</th><td>Progabide binds to both GABA<sub>A</sub> and GABA<sub>B</sub> receptors located on the terminals of primary afferent fibers. Binding to GABA<sub>A</sub> results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABA<sub>B</sub> receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.</td></tr><tr><th>Absorption</th><td>Well absorbed with a bioavailability of 60%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>4 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9959</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9534</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5085</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5433</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8381</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9194</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8307</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7538</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5797</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.507</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5455</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7138</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.6943</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6492</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8101</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.567
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8525
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9803
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4097 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8492
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5546
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>